REDWOOD CITY, Calif.,
Aug. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
(Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain, today announced that
Richard King, President and CEO,
will present a corporate overview at the Canaccord Genuity
33rd Annual Growth Conference at the Intercontinental
Boston, Boston, MA. The
presentation is scheduled for Thursday,
August 15, 2013 at 2:30 p.m.
ET/11:30 a.m. PT.
The presentation will be webcast live and can be accessed
through the Investors page at www.acelrx.com. For those not
available to listen to the live broadcast, a replay of the
presentations will be archived for 90 days and available through
the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
to solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine,
the invasive IV route of delivery and the complexity of infusion
pumps. AcelRx has announced positive results from each of the
three Phase 3 clinical trials for Zalviso and AcelRx anticipates
submitting a New Drug Application with the FDA in the third quarter
of 2013. AcelRx also announced positive top-line results for a
Phase 2 trial for ARX-04, a sufentanil formulation for the
treatment of moderate-to-severe acute pain, funded through a grant
from U.S. Army Medical Research and Materiel Command. The
company has two additional pain treatment product candidates,
ARX-02 and ARX-03, which have completed Phase 2 clinical
development. For additional information about AcelRx's
clinical programs, please visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to anticipated
timing of submission of the NDA and the therapeutic potential of
AcelRx Pharmaceuticals' product candidates. These
forward-looking statements are based on AcelRx Pharmaceuticals'
current expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
AcelRx Pharmaceuticals' ability to submit an NDA and receive
regulatory approval for Zalviso, that fact that FDA may dispute or
interpret differently positive clinical results obtained to date;
any delays or inability to obtain and maintain regulatory approval
of its product candidates, including Zalviso, in the United States and Europe; its ability to attract funding
partners or collaborators with development, regulatory and
commercialization expertise; its ability to obtain sufficient
financing to commercialize Zalviso; the market potential for
its product candidates; and other risks detailed in the "Risk
Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities
and Exchange Commission filings, including its Current Report on
Form 8-K filed with the SEC on July
19, 2013. AcelRx Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
(Logo:
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)
SOURCE AcelRx Pharmaceuticals, Inc.